Business
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (ȁ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development\n\n\n\n VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to highlight the strength and scientific leadership of its established Scientific Advisory Board (SAB). Rakovina’s SAB is composed of internationally recognized experts in oncology, AI-driven drug development, and precision medicine. The board plays a vital role in shaping the company’s research strategy, pipeline advancement, and translational development initiatives.\n \n\n\n Rakovina’s Scientific Advisory Board:\n \n\n\n\n Dr. Dennis Brown, SAB Chair,\n \n has been involved in cancer drug discovery and development for more than 35 years. Initially with the Stanford Research Institute at Stanford University where he was involved in drug-screening activities sponsored by the US National Cancer Institute. He has been co-founder of Matrix Pharmaceuticals (Chiron), ChemGenex (Cephalon/Teva), and Kintara (NASDAQ: KTRA); inventor on 40+ patents; former faculty at Harvard and currently President of Valent Technologies and chair of Mountain View Pharmaceuticals’ Board.\n \n\n\n Dr. Artem Cherkasov\n \n is the Canada Research Chair in Precision Cancer Drug Design, a Professor of Urologic Sciences at the University of British Columbia, and a Senior Scientist at the Vancouver Prostate Centre. He is a pioneer of the Deep Docking™ AI platform, which accelerates the screening of billions of compounds against DNA-damage response (DDR) targets. This groundbreaking technology led to a $142 million licensing deal with Roche—the largest in UBC’s history—and directly supports Rakovina’s AI-driven discovery programs.\n \n\n\n Dr. Petra Hamerlik\n \n is the Chair of Translational Neuro-Oncology at the University of Manchester. She previously served as Principal Scientist and CNS Cancer Bioscience Lead at AstraZeneca, where she advanced the development of brain-penetrant DNA-damage response inhibitors for the treatment of primary and metasta...